Enrollment Status: Open
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
We are looking for HIV+ people who are taking antiretroviral treatment (ART) and whose viral load is undetectable. The goal is to find out if IL-15 is safe alone or when used in combination with another treatment called broadly neutralizing antibodies (bNAbs). Participants will receive 8 doses of IL-15 given every 3 weeks. Half of the participants will be randomly assigned to also receive the bNAbs with it. After completing these treatments, participants will temporarily stop taking their HIV medicine (ART) and will be evaluated to see how well this treatment controls their viral load.
Basic Eligibility Criteria: